Skip to main content Accessibility help
×
Home

Article contents

P01-363 - Drug Treatment of Mild Cognitive Impairment

Published online by Cambridge University Press:  17 April 2020

R. Martínez de Velasco Soriano
Affiliation:
Hospital Universitario Ramon y Cajal, Madrid, Spain
E. Benítez Cerezo
Affiliation:
Hospital Universitario Ramon y Cajal, Madrid, Spain
C. Erausquin Sierra
Affiliation:
Hospital Universitario Ramon y Cajal, Madrid, Spain
I. Gobernado Ferrando
Affiliation:
Hospital Universitario Ramon y Cajal, Madrid, Spain
I. De la Serna De Pedro
Affiliation:
Hospital Universitario Ramon y Cajal, Madrid, Spain

Abstract

Introduction

Dementia is an acquired syndrome of organic nature, characterized by permanent impairment of memory and other intellectual functions, often associated with psychological and behavioral symptoms without impairment of consciousness. There are psychopathological manifestations.There are different subtypes of dementia. To determine a mild cognitive impairment, the average score of Minimental scale test must be between 21 and 26.

Clinical evidence

It has been shown that patients with cognitive impairment have a decreased activity of acetylcholine and increased activity of glutamate. Therefore there is a decline in cognitive ability with significant memory impairment and increased aurousal. There is an impairment of cognitive function to perceive, process and use information, which contributes, along with the intelligence, plan and solve problems, learn from the experience, plan tasks and predict results.

Hypothesis

For this postulate two fundamental ways in the treatment by use of cholinesterase inhibitors using memantine that blocks NMDA receptors.

Conclusions

However in mild cognitive impairment there is no evidence that these treatments improve patient outcome. Therefore we start treatment with cholinesterase inhibitors when Minimental score between 14 and 24. We'll use cholinesterase inhibitors in combination with memantine when the Minimental score between 10 and 14. We will use only memantine when the score between 3-14. It has been shown that only 30% of mild cognitive impairment progress to dementia. It is important to consider the use of these treatments because it is'nt shown a clear benefit in mild cognitive impairment and have side effects.

Type
Dementia / Gerontopshychiatry
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 13 *
View data table for this chart

* Views captured on Cambridge Core between 17th April 2020 - 25th January 2021. This data will be updated every 24 hours.

Access
Hostname: page-component-898fc554b-8ljtz Total loading time: 0.435 Render date: 2021-01-25T11:09:58.879Z Query parameters: { "hasAccess": "1", "openAccess": "0", "isLogged": "0", "lang": "en" } Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false }

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

P01-363 - Drug Treatment of Mild Cognitive Impairment
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

P01-363 - Drug Treatment of Mild Cognitive Impairment
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

P01-363 - Drug Treatment of Mild Cognitive Impairment
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *